Objective Comparison of Lesion Detectability in Low and Medium-energy Collimator Iodine-123 MIBG Images Using a Channelized Hotelling Observer

Overview

Journal Phys Med Biol

Publisher IOP Publishing

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Dec 16

PMID 27973344

Citations 1

Authors

Rebecca A Gregory

Iain Murray

Jonathan Gear

Matthew D Aldridge

Daniel Levine

Lucy Fowkes

Wendy A Waddington

Sue Chua

Glenn Flux

Affiliations

Soon will be listed here.

Abstract

Iodine-123 mIBG imaging is widely regarded as a gold standard for diagnostic studies of neuroblastoma and adult neuroendocrine cancer although the optimal collimator for tumour imaging remains undetermined. Low-energy (LE) high-resolution (HR) collimators provide superior spatial resolution. However due to septal penetration of high-energy photons these provide poorer contrast than medium-energy (ME) general-purpose (GP) collimators. LEGP collimators improve count sensitivity. The aim of this study was to objectively compare the lesion detection efficiency of each collimator to determine the optimal collimator for diagnostic imaging. The septal penetration and sensitivity of each collimator was assessed. Planar images of the patient abdomen were simulated with static scans of a Liqui-Phil anthropomorphic phantom with lesion-shaped inserts, acquired with LE and ME collimators on 3 different manufacturers' gamma camera systems (Skylight (Philips), Intevo (Siemens) and Discovery (GE)). Two-hundred normal and 200 single-lesion abnormal images were created for each collimator. A channelized Hotelling observer (CHO) was developed and validated to score the images for the likelihood of an abnormality. The areas under receiver-operator characteristic (ROC) curves, Az, created from the scores were used to quantify lesion detectability. The CHO ROC curves for the LEHR collimators were inferior to the GP curves for all cameras. The LEHR collimators resulted in statistically significantly smaller Azs (p < 0.05), of on average 0.891 ± 0.004, than for the MEGP collimators, 0.933 ± 0.004. In conclusion, the reduced background provided by MEGP collimators improved I mIBG image lesion detectability over LEHR collimators that provided better spatial resolution.

Citing Articles

Primary, scatter, and penetration characterizations of parallel-hole and pinhole collimators for I-123 SPECT.

Konik A, Auer B, De Beenhouwer J, Kalluri K, Zeraatkar N, Furenlid L Phys Med Biol. 2019; 64(24):245001.

PMID: 31746783 PMC: 8507420. DOI: 10.1088/1361-6560/ab58fe.

References

Huang S, Bolch W, Lee C, Van Brocklin H, Pampaloni M, Hawkins R . Patient-specific dosimetry using pretherapy [¹²⁴I]m-iodobenzylguanidine ([¹²⁴I]mIBG) dynamic PET/CT imaging before [¹³¹I]mIBG targeted radionuclide therapy for neuroblastoma. Mol Imaging Biol. 2014; 17(2):284-94. PMC: 4336853. DOI: 10.1007/s11307-014-0783-7. View

Yang L, Zhou J, Ferrero A, Badawi R, Qi J . Regularization design in penalized maximum-likelihood image reconstruction for lesion detection in 3D PET. Phys Med Biol. 2013; 59(2):403-19. PMC: 4254853. DOI: 10.1088/0031-9155/59/2/403. View

Matthay K, Shulkin B, Ladenstein R, Michon J, Giammarile F, Lewington V . Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer. 2010; 102(9):1319-26. PMC: 2865749. DOI: 10.1038/sj.bjc.6605621. View

Olivier P, Colarinha P, Fettich J, Fischer S, Frokier J, Giammarile F . Guidelines for radioiodinated MIBG scintigraphy in children. Eur J Nucl Med Mol Imaging. 2003; 30(5):B45-50. DOI: 10.1007/s00259-003-1138-9. View

Shidahara M, Inoue K, Maruyama M, Watabe H, Taki Y, Goto R . Predicting human performance by channelized Hotelling observer in discriminating between Alzheimer's dementia and controls using statistically processed brain perfusion SPECT. Ann Nucl Med. 2007; 20(9):605-13. DOI: 10.1007/BF02984658. View

Bal H, Guerin L, Casey M, Conti M, Eriksson L, Michel C . Improving PET spatial resolution and detectability for prostate cancer imaging. Phys Med Biol. 2014; 59(15):4411-26. PMC: 8375570. DOI: 10.1088/0031-9155/59/15/4411. View

Shapiro B, Gross M . Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implications of the use of 123I-MIBG. Med Pediatr Oncol. 1987; 15(4):170-7. DOI: 10.1002/mpo.2950150406. View

Gelfand M . Meta-iodobenzylguanidine in children. Semin Nucl Med. 1993; 23(3):231-42. DOI: 10.1016/s0001-2998(05)80104-7. View

Shapiro B, Gross M, Shulkin B . Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab. 2001; 12(10):469-75. DOI: 10.1016/s1043-2760(01)00492-1. View

10.

Gifford H, King M, de Vries D, Soares E . Channelized hotelling and human observer correlation for lesion detection in hepatic SPECT imaging. J Nucl Med. 2000; 41(3):514-21. View

11.

Hanley J, McNeil B . The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982; 143(1):29-36. DOI: 10.1148/radiology.143.1.7063747. View

12.

El Fakhri G, Surti S, Trott C, Scheuermann J, Karp J . Improvement in lesion detection with whole-body oncologic time-of-flight PET. J Nucl Med. 2011; 52(3):347-53. PMC: 3088884. DOI: 10.2967/jnumed.110.080382. View

13.

Monsieurs M, Brans B, Bacher K, Dierckx R, Thierens H . Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging. 2002; 29(12):1581-7. DOI: 10.1007/s00259-002-0973-4. View

14.

Macey D, Denardo G, Denardo S, Hines H . Comparison of low- and medium-energy collimators for SPECT imaging with iodine-123-labeled antibodies. J Nucl Med. 1986; 27(9):1467-74. View

15.

Metz C . Basic principles of ROC analysis. Semin Nucl Med. 1978; 8(4):283-98. DOI: 10.1016/s0001-2998(78)80014-2. View

16.

Bombardieri E, Giammarile F, Aktolun C, Baum R, Bischof Delaloye A, Maffioli L . 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; 37(12):2436-46. DOI: 10.1007/s00259-010-1545-7. View

17.

Dobbeleir A, Hambye A, Franken P . Influence of high-energy photons on the spectrum of iodine-123 with low- and medium-energy collimators: consequences for imaging with 123I-labelled compounds in clinical practice. Eur J Nucl Med. 1999; 26(6):655-8. DOI: 10.1007/s002590050434. View

18.

Barwick T, Murray I, Megadmi H, Drake W, Plowman P, Akker S . Single photon emission computed tomography (SPECT)/computed tomography using Iodine-123 in patients with differentiated thyroid cancer: additional value over whole body planar imaging and SPECT. Eur J Endocrinol. 2010; 162(6):1131-9. DOI: 10.1530/EJE-09-1023. View

19.

Snay E, Treves S, Fahey F . Improved quality of pediatric 123I-MIBG images with medium-energy collimators. J Nucl Med Technol. 2011; 39(2):100-4. DOI: 10.2967/jnmt.110.080309. View

20.

Inoue Y, Suzuki A, Shirouzu I, Machida T, Yoshizawa Y, Akita F . Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol. 2003; 10(6):623-32. DOI: 10.1016/s1071-3581(03)00652-4. View